What do Cochrane systematic reviews say about diabetic retinopathy? by Mozetic, Vania et al.
Sao Paulo Med J. 2017; 135(1):79-87    79
COCHRANE HIGHLIGHTSDOI: 10.1590/1516-3180.2016.0356040117
What do Cochrane systematic reviews say about  
diabetic retinopathy?
O que as revisões sistemáticas da Cochrane dizem sobre  
retinopatia diabética?
Vania MozeticI, Julia Pozzetti DaouII, Ana Luiza Cabrera MartimbiancoIII, Rachel RieraIV
Discipline of Evidence-Based Medicine, Escola Paulista de Medicina (EPM),  
Universidade Federal de São Paulo (Unifesp), São Paulo, Brazil
ABSTRACT
CONTEXT AND OBJECTIVE: Diabetic retinopathy is a disease caused by increased permeability of retinal 
vessels. Its incidence and prevalence have been increasing due to urbanization, greater life expectancy 
and the habits of modern life. Its onset is insidious and it may lead to blindness in 75% of individuals who 
have been diabetic for more than 20 years. The aim here was to evaluate the evidence from Cochrane 
systematic reviews on interventions relating to diabetic retinopathy. 
DESIGN AND SETTING: Review of systematic reviews, conducted at Cochrane Brazil.
METHODS: We included Cochrane systematic reviews on interventions relating to diabetic retinopathy. Two 
researchers evaluated the inclusion criteria, summarized the reviews and presented the results narratively. 
RESULTS: Ten reviews met the inclusion criteria. They showed some evidence of benefits from: 
(a) photocoagulation for diabetic retinopathy; (b) strict glucose and pressure control for postponing the 
onset of retinopathy; (c) antiangiogenic drugs for macular edema (high-quality evidence); (d) anti-vascular 
endothelial growth factor agents for proliferative diabetic retinopathy (very low to low-quality evidence); 
and (e) intravitreal injection or surgical implantation for treating persistent or refractory macular edema. 
However, blood pressure control seems to have no benefit after the onset of retinopathy. 
CONCLUSION: Only a few options are likely to be effective for treating diabetic retinopathy. These include 
photocoagulation and anti-vascular endothelial growth factor agents. Strict glucose and pressure control 
seem to postpone the onset of retinopathy. For macular edema, antiangiogenic drugs, intravitreal injection 
and surgical implantation seem to have some benefit. 
RESUMO 
CONTEXTO: A retinopatia diabética é uma doença causada pelo aumento da permeabilidade dos vasos 
da retina. Sua incidência e prevalência vêm aumentando devido à urbanização, maior expectativa de vida 
e hábitos de vida modernos. Seu início é insidioso e pode levar à cegueira em 75% dos pacientes diabéti-
cos com mais de 20 anos de doença. O objetivo foi avaliar a evidência das revisões sistemáticas Cochrane 
sobre intervenções para retinopatia diabética. 
TIPO DE ESTUDO E LOCAL: Revisão de revisões sistemáticas conduzida no Centro Cochrane do Brasil.
MÉTODOS: Nós incluímos revisões sistemáticas Cochrane sobre intervenções para retinopatia diabética. 
Dois pesquisadores avaliaram os critérios de inclusão, resumiram as revisões e apresentaram os resultados 
narrativamente. 
RESULTADOS: Dez revisões preencheram os critérios de inclusão e mostraram benefícios com: (a) foto-
coagulação para retinopatia diabética; (b) controle rigoroso da glicose e da pressão para adiar o início da 
retinopatia; (c) fármacos antiangiogênicos para edema macular (evidência de alta qualidade); (d) agen-
tes antifator de crescimento do endotélio vascular para retinopatia diabética proliferativa (evidência de 
qualidade muito baixa a baixa); (e) injeção intravítrea ou implante cirúrgico para o tratamento do edema 
macular persistente ou refratário. No entanto, o controle da pressão arterial parece não ter benefício após 
o início da retinopatia. 
CONCLUSÃO: Existem poucas opções provavelmente efetivas para o tratamento da retinopatia diabé-
tica. Estas incluem fotocoagulação e agentes antifator de crescimento do endotélio vascular. O controle 
rigoroso da glicose e da pressão parecem adiar o início da retinopatia. Para o edema macular, fármacos 
antiangiogênicos, injeção intravítrea e implante cirúrgico parecem ter algum benefício. 
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INTRODUCTION
Diabetic retinopathy is a secondary retinal disease caused by 
vascular changes due to diabetes. It is a common complication 
of diabetes and is the leading cause of decreased vision in the 
economically active population, with large negative impacts 
both on public health and on the social security system. It has 
been estimated that, because of increased life expectancy and 
lifestyle changes associated with urbanization, the worldwide 
prevalence of diabetes will rise from 126.6 million in 2010 to 
191 million in 2030.1
According to the World Health Organization, 75% of patients 
with a 20-year history of type 2 diabetes have some degree of reti-
nopathy.2 Nonetheless, there is still no intervention capable of pre-
venting the emergence of retinopathy or even of preventing its pro-
gression, effectively and safely. Thus, clinical practice is limited to 
guidance for patients in which they are advised to maintain strict 
glycemic control because of the risk of disease evolution.
Like other vascular changes in diabetic patients, retinopathy 
starts in the endothelium. This tissue modulates vascular functions 
through releasing or inhibiting nitric oxide, endothelin, angio-
tensin and other substances that act in relation to inflammation, 
platelet aggregation, permeability, oxidative stress, blood clotting 
and vascular tone.3-7 
Diabetic retinopathy is classified based on the degree of 
involvement of the retinal tissue and may be early non-prolif-
erative, moderate non-proliferative, severe non-proliferative or 
proliferative.8 Early non-proliferative retinopathy is character-
ized by microaneurysms seen via fundoscopy; while in moder-
ate non-proliferative (or exudative) retinopathy, it is possible to 
observe hard exudates. In severe non-proliferative retinopathy, 
in addition to the previous changes, there are soft exudates (ret-
inal ischemia), intraretinal abnormalities (intra-microvascular 
retinal anomalies, IRMA) and vessels “on rosary beads”.8 Finally, 
in proliferative retinopathy, there is vascular neoformation with 
blood extravasation, culminating in vitreous hemorrhage. At the 
most advanced stage, the new vessels can lead to retinal traction 
with subsequent retinal detachment.9
Diabetic retinopathy is diagnosed through observation of the 
changes described above through direct and indirect fundoscopy, 
retinography, photographic records of the retina or angiofluor- 
esceinography.8,9 Early diagnosis is crucial for the best response 
to treatments, since more advanced degrees of retinopathy have 
worse prognoses.
Evaluations on diabetic patients without changes seen via fun-
doscopy or on those with early non-proliferative diabetic retinopa-
thy need to be made annually. Those with moderate non-prolifera-
tive diabetic retinopathy need to be evaluated every six months, and 
those with severe non-proliferative retinopathy, every two to four 
months.10 Patients with macular edema also need to be reevaluated 
within six months, because if this is persistent, treatment with a 
macular grid is necessary in order to preserve central vision.10
Diabetic macular edema is a complication of diabetic retinopa-
thy. It is defined as clinically significant macular edema when it is 
observed in the presence of hard exudates less than 500 µm from 
the center of the fovea and/or retinal edema; or if the size of the 
macular edema is larger than the papillary diameter (1500 µm) 
of the fovea, with the presence of edema, microaneurysms, soft 
exudates (areas of retinal ischemia) and hard exudates (lipopro-
tein buildups).10,11 The diagnosis of clinically significant macular 
edema is made by means of posterior pole biomicroscopy using 
drug-induced mydriasis.10,11
The practical approach most used for preventing diabetic 
retinopathy is strict glucose control and regular eye tracking. 
The therapeutic options include laser phototherapy, which includes 
photocoagulation and photostimulation; injection of intravit-
real corticosteroids; and use of anti-vascular endothelial growth 
factor (VEGF) drugs (pegaptanib, ranibizumab, aflibercept and 
bevacizumab).
It is important to note that once macular disease has become 
established, treatment for diabetic retinopathy becomes essential 
and haste is required. On the other hand, although the thera- 
peutic options available seem effective, they are invasive and 
may be associated with serious adverse events, such as visual 
field loss, reduced night vision, increased intraocular pressure 
and endophthalmitis.
Considering the global prevalence of diabetic retinopathy, its 
comorbidities, the consequences associated with its development 
and the uncertainties regarding the effectiveness and safety of the 
preventive and therapeutic interventions available, it is relevant to 
assess the current literature in order to summarize the best evi-
dence that can guide decision-making processes relating to this 
important public health problem and direct future research, so as 
to answer questions that still remain unanswered.
OBJECTIVES
To evaluate the evidence from Cochrane systematic reviews 
regarding the effectiveness and safety of interventions for pre-
vention and treatment of diabetic retinopathy. 
METHODS
Design
This was a review of systematic reviews.
Setting
This review was conducted within the Postgraduate Program on 
Evidence-Based Health, of the Federal University of São Paulo 
(Unifesp) and at Cochrane Brazil.
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Criteria for including reviews
We only included the last version of completed Cochrane system-
atic reviews that evaluated the effects of different interventions 
for preventing or treating diabetic retinopathy. The protocols of 
systematic reviews in progress and withdrawn reviews were not 
considered.
Search for reviews
We carried out an electronic search in the Cochrane Library (via 
Wiley) on August 5, 2016, as presented in Table 1. 
Selection of reviews 
Two researchers independently selected and evaluated all the sys-
tematic reviews retrieved, in order to confirm their eligibility, in 
accordance with the inclusion criteria.
Presentation of results
We presented all the included reviews narratively (qualitative 
synthesis). We considered that the key points regarding their 
relevance were the methods used, quality of studies included, 
results, quality of the body of final evidence for each outcome 
and applicability. 
RESULTS
An initial search resulted in 21 reviews and, after reading the titles 
and abstracts, ten Cochrane systematic reviews (SRs) were found 
to be actually related to the topic and fulfilled the inclusion cri-
teria. These were then summarized and are presented below.12-21
1. Anti-vascular endothelial growth factor for prevention  
of postoperative vitreous cavity haemorrhage after 
vitrectomy for proliferative diabetic retinopathy
Vitreous hemorrhage after vitrectomy in patients with diabetic 
retinopathy is a major complication. In this review,12 the authors 
proposed to assess the use of anti-vascular endothelial growth fac-
tor (VEGF) after vitrectomy. Their review included randomized 
clinical trials (RCTs) and “quasi” randomized trials on anti-VEGF, 
to evaluate the incidence of vitreous hemorrhage post-vitrectomy 
in patients with proliferative diabetic retinopathy. Twelve RCTs of 
moderate quality were included, totaling 654 eyes, on patients who 
received bevacizumab preoperatively or intraoperatively. 
Participants who received bevacizumab intravitreally, in asso-
ciation with vitrectomy, developed less early vitreous hemorrhage 
than did those who underwent vitrectomy alone. However, the 
effect of administering bevacizumab preoperatively or intraop-
eratively to prevent late vitreous hemorrhage was uncertain (risk 
relative, RR 0.72; 95% confidence interval, CI: 0.30 to 1.72; three 
studies on 196 eyes, with poor quality of evidence). No local or 
systemic complications were reported. The risk of retinal detach-
ment was low among individuals who received preoperative or 
intraoperative treatment with bevacizumab (RR 0.46; 95% CI: 0.19 
to 1.08; 7 studies on 372 participants, with low quality of evi-
dence). The authors concluded that use of bevacizumab slowed 
the incidence of early vitreous hemorrhage following vitrectomy. 
The complications seemed few and it was believed that other 
ongoing studies would strengthen decision-making regarding 
use or nonuse of this drug.
2. Topical non-steroidal anti-inflammatory agents  
for diabetic cystoid macular edema
Cystoid diabetic macular edema, i.e. accumulation of fluid in 
the inner layers of the retina, is a painless complication leading to 
reduction or fluctuation of central vision. It may resolve sponta-
neously, but if it persists, it can lead to permanent loss of vision. 
It is probably related to inflammatory processes. Therefore, several 
topical non-steroidal anti-inflammatory drugs (NSAIDs), such as 
0.09% bromfenac, 0.1% nepafenac and 0.5% ketorolac have been 
used to treat chronic diabetics with cystoid macular edema (CMO). 
The aim of these authors’ review13 was to select randomized 
clinical trials and “quasi” randomized trials in order to discover the 
effects of topical NSAIDs among diabetics with CMO. However, 
no study was included, since most of the studies were conducted 
on pseudophakic patients. Presence of pseudophakia can be con-
sidered misleading. The authors suggested that there was a need 
for studies on the use of NSAIDs among diabetic patients with 
cystoid macular edema. 
They concluded that there was a need to conduct properly 
designed studies in order to clarify the action of this proposed 
intervention on the clinical condition.
3. Blood pressure control for diabetic retinopathy
These authors’14 objective was to gather evidence regarding 
whether hypertension control had protective action relating to 
prevention and evolution of diabetic retinopathy, thereby preserv-
ing visual acuity, through measuring adverse events, quality of life 
and costs. Secondarily, they aimed to assess the behavior of differ-
ent classes of antihypertensive drugs regarding the same outcomes. 
Fifteen clinical trials were included in this review, with varying fol-
low-up times, on a total of 4,157 type 1 diabetic patients and 9,512 
type 2 diabetic patients, with or without hypertension. The patients 
were randomized into groups with intensive pressure control ver-
sus less intensive control; standard blood pressure care versus any 
care; and different classes of antihypertensive drugs versus placebo.
Table 1. Search strategy for Cochrane Library
#1 
“Diabetic retinopathy” (MeSH term) (search in Title, Abstract, 
Keywords)
#2 #1 and filter “in Cochrane reviews”
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Among type 1 diabetic patients, one out of five studies reported 
the incidence of diabetic retinopathy and one reported its progres-
sion over four to five years of treatment and follow-up; four studies 
assessed a composite outcome of incidence and progression along 
over the same period. Among the type II patients, five out of ten 
trials reported on the incidence and three reported on the progres-
sion of retinopathy; one out of these ten trials reported on both 
the incidence and the progression over the same time interval of 
four to five years. A test done among type II diabetic patients did 
not report the outcomes of interest for this review.
The evidence from these clinical trials showed that there was 
a benefit from treatment with intensive pressure control over a 
follow-up of four to five years, regarding the incidence of diabetic 
retinopathy (RR 0.8; 95% CI: 0.71 to 0.92) and the combined out-
come of incidence/progression (RR 0.78; 95% CI: 0.63 to 0.97). 
The evidence showed that there was less benefit regarding pro-
gression over the same time interval of four to five years (RR 0.88; 
95% CI: 0.73 to 1.05). Pressure control did not have any benefit 
regarding the progression of proliferative diabetic retinopathy, 
clinically significant macular edema or moderate to severe loss of 
visual acuity (RR 0.95; 95% CI: 0.83 to 1.09 for macular edema; 
and RR 1.06; 95% CI: 0.85 to 1.33 for visual acuity with the best 
correction), also over the same range of four to five years.
In 7 of the 15 trials, the adverse effect reported most often was 
death, which led to an estimated RR of 0.86 (95% CI: 0.64 to 1.14); 
Three trials reported hypotension as an adverse event (RR 2.08; 
95% CI: 1.69 to 2.57). Ocular adverse events were described in 
individual trials.
In this review, the authors concluded that pressure control had 
a beneficial effect regarding prevention of diabetic retinopathy, but 
that there was no evidence that the intervention might slow down 
the progression of retinopathy.
4. Laser photocoagulation for proliferative diabetic retinopathy
Diabetic retinopathy is a complication of diabetes in which 
high glycemic indexes lead to damage to retinal vessels. Laser is 
one therapeutic option. The objective of this study15 was to com-
pare laser photocoagulation with no treatment or other treatments 
among patients with pre-proliferative diabetic retinopathy. 
These authors selected randomized clinical trials on patients 
with this profile and allocated them into groups of photocoag-
ulation with any type of laser other than xenon or ruby laser. 
They excluded trials that compared treatments using different 
laser wavelengths, exposure times and powers of intensity, with 
absence of treatment or use of other treatments. The primary 
outcome was considered to be loss of three lines (15 or more 
letters) from visual acuity with the best correction, over two to 
five years. Five clinical trials totaling 4,786 people (9,503 eyes) 
were included in this review. 
The authors took all studies with a risk of bias of execution into 
consideration. Three studies did not show any risk of bias due to 
attrition. The authors joined the data using a random effects model, 
except if there were three trials or fewer, in which case they used 
a fixed-effect model. They found that there was considerable het-
erogeneity among the trials, with I² greater than 50%. 
In the 12th month of follow-up, there was no difference between 
the eyes that had received photocoagulation and the eyes that had 
no treatment or another treatment, regarding a loss of visual acu-
ity of 15 or more letters (RR 0.99; 95% CI: 0.89 to 1.11; two clini-
cal trials on 8926 eyes, with low quality of evidence). Long-term 
follow-up did not show any consistency, but one study showed 
that photocoagulation reduced the risk of loss of accuracy of 15 
letters or more over five years by 20%. Laser treatment reduced 
the risk of severe loss of visual acuity over twelve months by 50% 
(RR 0.46; 95% CI: 0.24 to 0.86; four clinical trials on 9,276 eyes, 
with moderate quality of evidence).
There was a beneficial effect on the progression of diabetic 
retinopathy in eyes that were treated, with a 50% reduction in the 
risk of progression of diabetic retinopathy (RR 0.49; 95% CI: 0.37 
to 0.64; four clinical trials on 8,331 eyes, with low quality of evi-
dence) and similar reductions in the risk of vitreous hemorrhage 
(RR 0.56; 95% CI: 0.37 to 0.85; two clinical trials on 224 eyes, with 
low quality of evidence).
The authors concluded that laser photocoagulation remained 
the treatment of choice for proliferative diabetic retinopathy and 
suggested that studies combining photocoagulation with anti-
angiogenic treatment (VEGFs) should be developed.
5. Anti-vascular endothelial growth factor  
for proliferative diabetic retinopathy
Given that photocoagulation, the treatment of choice for dia-
betic retinopathy, has side effects of affecting the field of view and 
limiting night vision, the authors of this review16 investigated the 
efficiency and effectiveness of use of vascular endothelial growth 
factor (VEGF) as a treatment that might preserve the vision of 
patients with proliferative diabetic retinopathy. For this, the authors 
searched for randomized clinical trials comparing VEGF with 
sham or in combination with other treatments, among patients 
with proliferative diabetic retinopathy. They found 18 randomized 
clinical trials on a total of 1,005 patients (1,131 eyes). Eight clini-
cal trials recruited patients referred for photocoagulation, nine for 
vitrectomy and one for fasciectomy, all with a mean follow-up of 
six months and ranges from one to twelve months. Seven studies 
showed a high risk of bias and the others had dubious risk of bias 
in one or more domains.
A study with a very low level of evidence, on 61 patients, showed 
that individuals treated with bevacizumab and panretinal pho-
tocoagulation were less likely to have lost three or more lines of 
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visual acuity after 12 months, compared with those treated with 
panretinal photocoagulation alone (RR 0.19; 95% CI: 0.05 to 0.81). 
Patients treated with anti-VEGF had a higher chance of gaining 
three or more lines of vision acuity, but the effect was imprecise 
and compatible with no effect (RR 0.37; 95% CI: 6.78 to 125.95). 
No other study noted these two outcomes. On average, people 
treated with anti-VEGF (bevacizumab, ranibizumab or pegaptanib) 
had improved visual acuity at 12 months, compared with people 
who did not receive anti-VEGF (mean difference, MD -0.07; 95% 
CI of logarithm of the minimum angle of resolution (logMAR): 
-0.12 to -0.02; five clinical trials on 373 participants, with low qual-
ity of evidence). There was evidence suggesting that proliferative 
diabetic retinopathy regressed through reduction of leakage, seen 
on angiofluoresceinography, but it was difficult to estimate a result 
from judging only two studies. People receiving anti-VEGF were 
less likely to have vitreous bleeding or preretinal bleeding after 
12 months (RR 0.32; 95% CI: 0.16 to 0.65; three trials on 342 par-
ticipants, with low quality of evidence). No study reported health-
related quality of life or fluorescein leakage. 
People treated with bevacizumab and vitrectomy were less 
likely to lose three or more lines of vision after 12 months than 
were those treated with vitrectomy, but the effect was imprecise 
and compatible with no effect or closer to loss of vision (RR 0.49; 
95% CI: 0.08 to 3.14; three trials on 94 participants, with low qual-
ity of evidence).
People treated with bevacizumab were more likely to gain three 
or more lines of vision (RR 1.62; 95% CI: 1.20 to 2.17; three trials 
on 94 participants, with low quality of evidence). In general, people 
treated with bevacizumab had better visual acuity after 12 months, 
compared with people who had not received bevacizumab, but 
there were doubts regarding the estimates. The confidence inter-
val included zero, i.e. compatible with no effect, and there was 
considerable inconsistency between the studies (MD -0.24; 95% 
CI logMAR: -0.50 to 0.01; six clinical trials on 335 people, with I² 
= 67% and low quality of evidence). People who received bevaci-
zumab were less likely to have pre-retinal or vitreous hemorrhage 
after 12 months (RR 0.30; 95% CI: 0.18 to 0.52; seven clinical tri-
als on 393 participants, with low quality of evidence). No study 
reported on quality of life. Adverse effects were rarely reported and 
there was no evidence of any increased risk with anti-VEGF, but 
there were relatively few studies that reported these effects and the 
event occurred at a low rate. Thus, the power of analysis to detect 
any differences was low. The authors considered that the quality 
of the studies was suspect, with inaccuracy and inconsistency in 
assessing the risk of bias.
The authors concluded that the evidence from these clinical tri-
als measuring the effectiveness and safety of anti-VEGF, for use in 
treating proliferative diabetic retinopathy to achieve standard ben-
efits, was of low or very low quality. However, the results suggested 
that anti-VEGFs can reduce the risk of intraocular hemorrhage in 
people with proliferative diabetic retinopathy and that new clinical 
trials to elucidate these questions should be conducted carefully.
6. Anti-vascular endothelial growth factor  
for diabetic macular oedema
Diabetic macular edema is a common complication of diabetic 
retinopathy treated with grid or focal laser in order to prevent loss 
of vision. However, this treatment rarely improves vision. Thus, use 
of anti-VEGF has been proposed. 
These authors17 investigated the effects of preserving or improv-
ing vision, acceptance, security and quality of life with this drug. 
They included randomized clinical trials comparing anti-VEGF 
drugs versus sham, other treatments or no treatment, in relation 
to outcomes of gain or loss of visual acuity of three or more lines, 
over follow-up periods of up to one year (estimated average of 
six months).
Eighteen studies were selected. It was concluded that over a 
one-year period, patients who underwent anti-VEGF treatment 
gained three or more lines of vision, compared with those treated 
using a grid (RR 3.6; 95% CI: 2.7 to 4.8; 10 trials on 1,333 cases, 
with high quality of evidence) and had less chance of losing three 
or more lines of vision (RR 0.11; 95% CI: 0.05 to 0.24; seven stud-
ies on 1,086 cases, with high quality of evidence). It was estimated 
that eight out of 100 patients with diabetic macular edema were 
able to gain three or more lines of vision by means of a macular 
grid, whereas 28 patients would achieve this through antiangio-
genic therapy. Thus, 100 patients would need to be treated with 
antiangiogenic therapy in order to improve the vision of 20 patients 
(number need to treat, NNT = 20; 95% CI: 13-29). 
People treated with anti-VEGF had an improvement of 1.6 
sight lines on average (95% CI: 1.4 to 1.8) after one year, compared 
with those who received pan-laser photocoagulation (nine stud-
ies on 1,292 cases, with high quality of evidence). For this, seven 
to nine injections were applied during the first year and three or 
four in the second year, in larger studies, with monthly or fixed 
follow-up. Compared with sham treatment, the antiangiogenic 
was more effective (three studies on 919 participants, with high-
quality evidence). Ocular adverse effects such as endophthalmitis 
were rare in the studies included. 
A meta-analysis conducted on all the antiangiogenic drugs, 
compared with sham or photocoagulation, showed that there was 
no significant difference in relation to adverse systemic effects 
(15 studies with 441 events among 2985 participants; RR 0.98; 
95% CI: 0.83 to 1.17), arterial thromboembolic events (14 studies 
with 129 events among 3034 participants; RR 0.89; 95% CI: 0.63 
to 1.25) and overall mortality (63 events among 3562 participants; 
RR 0.88; 95% CI: 0.52 to 1.47). The authors judged that the quality 
of evidence regarding side effects was moderate because the safety 
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scores were only modest and because participants with prior car-
diovascular events had been excluded in some studies.
The authors concluded that there was high-quality evidence 
favoring use of antiangiogenic drugs, compared with photoco-
agulation, over a period of one to two years. They suggested that 
future studies should examine the real-world differences in effec-
tiveness between the drugs used in studies monitoring patients at 
high cardiovascular risk.
7. Intensive glucose control versus conventional  
glucose control for type 1 diabetes mellitus
In this review,18 the authors analyzed the effects of strict glu-
cose control versus conventional control, and evaluated whether 
blood glucose at below normal or at normal levels brought bene-
fits. A search for randomized trials on type I diabetics with follow-
ups of at least one year that had been published up to 2012 was 
conducted. Twelve clinical trials were found, with a total of 2,230 
patients with a broad-spectrum population, with follow-ups vary-
ing from one to six and a half years. Because of the nature of the 
intervention, these studies could not be “blinded” to hypoglyce-
mia. Moreover, 50% of these studies were judged to present high 
risk of bias in at least one other category.
In the group with strict glucose control, the risk of develop-
ing microvascular complications was lower than in the group with 
conventional treatment: 23/371 (6.2%) versus 92/397 (23.2%); 
RR 0.27; 95% CI: 0.18 to 0.42; P < 0.00001; two clinical trials on 
768 participants, with high quality of evidence. Regarding the pro-
gression of the disease manifested in cases of retinopathy, the effect 
was weaker. For retinopathy, intensive glucose control reduced the 
risk of progression in studies with a duration of follow-up of at 
least two years: 85/366 (23.2%) versus 154/398 (38.7%); RR 0.61; 
95% CI: 0.49 to 0.76; P < 0.0001; two trials on 764 participants, 
with moderate quality of evidence. On the other hand, there was 
evidence for an initial worsening of retinopathy after only one year 
of intensive glucose control: 17/49 (34.7%) versus 7/47 (14.9%); 
RR 2.32; 95% CI: 1.16 to 4.63; P = 0.02; two trials on 96 partici-
pants, with low quality of evidence).
Strict control increased the risk of hypoglycemia. However, 
the studies were heterogeneous, and only one study, the “Diabetes 
Complications Clinical Trial (DCCT)”, clearly showed any increase 
in episodes of severe hypoglycemia. Mortality was very low in all 
the studies.
8. Pentoxifylline for diabetic retinopathy
Vascular occlusion is a leading cause of diabetic retinopathy, 
since chronic high glucose levels leads to changes in the vascu-
lar endothelium that culminate in arteriolar occlusion and poor 
retinal tissue perfusion, rather than nourishment of these isch-
emic areas though stimulation from vascular proliferation factors. 
Pentoxifylline is a drug used in treating occlusive peripheral arterial 
diseases. Thus, there are clinical trials in the literature that address 
this subject. However, the authors of this systematic review19 failed 
to include any study in their review because none of them met the 
inclusion criteria proposed in their protocol.
These authors concluded that photocoagulation remained the 
first choice for treating diabetic retinopathy. However, there was evi-
dence that pentoxifylline would induce decreased proteinuria and 
albumin excretion, and would also normalize some blood patterns. 
Diabetic patients treated with pentoxifylline had early absorption 
of retinal hemorrhage and had less neovascularization. In some 
cases, there was a reduction of ischemic areas. These results sug-
gested that pentoxifylline might be effective in preventing retinal 
neovascularization and improving this condition. The authors sug-
gested that further randomized clinical trials should be conducted 
to assess the treatment. These would be needed in order to prove 
the efficacy and effectiveness of pentoxifylline in relation to the 
evolution of diabetic retinopathy.
9. Vitamin C and superoxide dismutase (SOD)  
for diabetic retinopathy
This Cochrane review aimed to study the effects of vitamin 
C and superoxide dismutase (SOD), as antioxidants for treating 
diabetic retinopathy, given the growing evidence of the oxidizing 
action of this disease. The authors20 only took clinical trials with 
one or both drugs into consideration. No studies that assessed treat-
ment of diabetic retinopathy with vitamin C and SOD to indicate 
whether these substances had any impact on the evolution of the 
disease were found.
The authors stated that photocoagulation remained the treat-
ment of choice for diabetic retinopathy, although there was evi-
dence that free radicals had a role in the pathogenesis of the dis-
ease. They considered that antioxidant therapy could be helpful in 
preventing the progression of retinopathy, and that a combination 
of drugs could be needed in order to prevent visual loss among 
diabetic patients.
10. Intravitreal steroids for macular edema in diabetes
In this study,21 the authors evaluated the safety and effective-
ness of any form of steroids applied intravitreally to treat diabetic 
macular edema up to 2007. Seven studies on 632 eyes were included. 
Four studies reported on intravitreal injection of triamcinolone 
(IVTA), compared with other treatments, by assessing visual acuity 
after three, six, nine and 24 months. They showed that intravitreal 
steroids were more beneficial. Three studies examined intravitreal 
application of fluocinolone acetate implants (FAI) or systemic 
administration of dexamethasone (DDS). Two studies presented 
low risk of bias, one had medium risk, two had high risk and two 
had unclear risk. The results suggested that IVTA had a major 
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beneficial effect regarding both visual acuity and retinal thick-
ness. Two trials reported that clinical improvements were achieved 
through FAI, in comparison with the standard treatment, although 
severely decreased visual acuity was not unusual. Beneficial effects 
were also observed in a study using DDS, although endophthal-
mitis was observed and two patients presented ptosis: one with 
a conjunctival ulcer and one with retinal detachment. Increased 
intraocular pressure and cataract formation are side effects that 
require monitoring.
These authors concluded that intravitreal injectable steroids 
or implantable steroids improved visual acuity in cases of diabetic 
macular edema that were persistent or recurrent. However, they 
stated that the question of whether the same beneficial behavior in 
the early stages of the disease would be obtained, both with their 
use alone and in association with photocoagulation, remained open. 
Treatment with DDS can have positive effects in cases of refrac-
tory persistent edema or in cases in which the standard treatment 
was insufficient. However, because of the variety of protocols, it has 
not been possible to identify an algorithm for its use in practice. 
Given that the half-life of DDS is short, patients need to be sub-
jected to repeated injections, which increases the risk of compli-
cations relating to the procedure, such as endophthalmitis, retinal 
detachment and vitreous hemorrhage. FAI can solve the problem 
of complications due to injections, through having a more sus-
tained effect, but it has higher risk of increased intraocular pres-
sure, which would require medical or surgical intervention, in addi-
tion to greater risk of development of cataracts. No studies have 
addressed the effects of treatment according to diabetic macular 
edema stage, either as single or as combined therapy.
DISCUSSION
Among the ten SRs found in the Cochrane Library that discuss 
interventions relating to diabetic retinopathy, four present sys-
temic strategies that might have a preventive nature, such that 
they might prevent progression of the disease. These strategies 
would have the capacity to act throughout the microcirculation. 
The other six SRs analyzed local treatments for disease that had 
already become established.
It can be noted that among the four SRs presenting systemic 
interventions, “Blood pressure control for diabetic retinopathy” 
and “Intensive glucose control versus conventional glucose con-
trol for type 1 diabetes mellitus” were the ones that addressed 
prevention and progression of diabetic retinopathy. In the other 
two, “Vitamin C and superoxide dismutase (SOD) for diabetic 
retinopathy” and “Pentoxifylline for diabetic retinopathy”, the 
authors were unable to find relevant clinical trials and, in accor-
dance with their predefined inclusion criteria, they left the topic 
open for future clinical trials, thereby revealing the need to study 
these issues.
The SR on the systemic intervention “Blood Pressure control 
for diabetic retinopathy” showed that there was a benefit from low-
ering blood pressure in relation to prevention of diabetic retinopa-
thy that lasted for four or five years. However, it lacked evidence to 
show that this would slow the progression of diabetic retinopathy. 
This, together with the modest beneficial effect on disease incidence, 
weakened the conclusion that there was a benefit from interven-
ing in blood pressure only to prevent diabetic retinopathy. In the 
review “Intensive glucose control versus conventional glucose con-
trol for type 1 diabetes mellitus”, there was high-quality evidence 
showing that strict glycemic control decreased the development of 
retinopathy complications, compared with standard control among 
young patients. However, the evidence relating to disease progres-
sion was weaker. These authors suggested that studies addressing 
the same outcomes among elderly patients with this disease and 
macrovascular complications should be conducted.
Systemic interventions, by their very nature, may be the 
most appropriate form of prevention for retinopathy. It is clear 
that there is a need for more studies with higher levels of evi-
dence on prophylactic action through the microcirculation, and 
even on prevention relating to diabetic macrocirculation. These 
studies should be conducted not only on different populations, 
as suggested by the authors of several of the abovementioned 
reviews, but also on other pharmacological classes that act pre-
ventively. For example, lipid-lowering drugs are known to protect 
the macrocirculation, but their behavior in relation to the micro- 
circulation remains a mystery.
Among the six SRs that investigated local therapy, three 
addressed anti-VEGFs: two of these reviews analyzed studies 
on proliferative diabetic retinopathy and one, macular edema. 
One review examined clinical trials involving topical corticoste-
roid therapy for diabetic macular edema, and another assessed 
the use of non-steroidal anti-inflammatory drugs to treat cystoid 
macular edema. The last of these reviews examined clinical trials 
on photocoagulation.
In the SR “Topical non-steroidal anti-inflammatory agents 
for diabetic cystoid macular oedema”, the authors did not include 
any clinical trials that might address the use of non-steroidal anti-
inflammatory drugs for treating cystoid macular edema. This was 
because all the studies eventually fell within the exclusion criteria 
due to the large number of confounding factors relating to the dif-
ferent etiologies of this pathological condition.
The SR “Laser photocoagulation for proliferative diabetic reti-
nopathy” included five trials that did not address near vision or 
quality of life among the patients who received this treatment. 
It found that there was little difference in visual acuity between 
the control group and intervention group after a twelve-month 
period, with low quality of evidence. There was moderate quality 
of evidence regarding reduction of the risk of severe loss of visual 
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acuity. There was a benefit regarding progression of diabetic reti-
nopathy in the intervention group, with low quality of evidence, 
and also a benefit regarding vitreous hemorrhage.
In the SR “Anti-vascular endothelial growth factor for pro-
liferative diabetic retinopathy”, the authors concluded that there 
was low or very low quality of evidence regarding the safety and 
efficacy of the use of anti-VEGFs in relation to proliferative dia-
betic retinopathy. However, they suggested that an improvement 
was obtained regarding vitreous hemorrhage. This went against 
the conclusion from the review “Anti-endothelial vascular growth 
factor for prevention of postoperative vitreous cavity haemorrhage 
after vitrectomy for proliferative diabetic retinopathy”, which was 
a review with high-quality evidence.
Among these six SRs, many concluded that the procedure 
investigated was advantageous. On the other hand, they suggested 
that further studies should be conducted on patients presenting 
different profiles or at earlier stages of the disease, or using asso-
ciations between the therapies to enhance their effectiveness and 
reduce the side effects foreseen in the procedures.
Regarding visual acuity, the use of anti-VEGF in treating pro-
liferative retinopathy was found to improve visual acuity, with low 
quality of evidence. There was high-quality evidence regarding its 
use in macular treatment, compared with use of a macular grid.
As stated earlier, diabetic retinopathy is a disease that causes a 
negative impact on both health and social security through affect-
ing the economically active population. It also affects patients’ self-
esteem, because of its deleterious and mutilating nature.
The treatment of choice for proliferative diabetic retinopathy 
continues to be peripheral retinal photocoagulation. However 
for treating macular disease, the use of injectable corticosteroids 
and anti-VEGFs is of great interest with regard to preserving and 
improving patients’ vision. These methods are promising alterna-
tives for treating diabetic macular edema, but further studies on 
the early phase of this pathological condition are required.
Regarding the implications of the present review for further 
research, the need for a prophylactic treatment or an option 
capable of at least reducing the progression of diabetic reti-
nopathy persists even today. The aim of such treatment would 
be to avoid local treatments, thereby preserving the retinal tis-
sue. Thus, the search for systemic medication that can produce 
effects on the entire vascular endothelium continues, with the 
aim of safeguarding diabetic patients’ macro and microcircula-
tion and acting as prophylaxis to avoid all the sequelae that dia-
betes causes to the vascular tree.
CONCLUSION 
Only a few options are likely to be effective for treating diabetic 
retinopathy. These include photocoagulation and anti-vascu-
lar endothelial growth factor agents. Strict glucose and pressure 
control seem to postpone the onset of retinopathy. For macular 
edema, antiangiogenic drugs, intravitreal injection and surgical 
implantation seem to have some benefit. However, these find-
ings came from evidence ranging from low to high quality. Low-
quality evidence needs to be used with caution in clinical practice 
until further studies can corroborate it. 
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